PARNAX LAB
|
PARNAX LAB Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.25 | 10.03 | 8.37 | 7.50 | 8.40 |
| CEPS(Rs) | 17.28 | 16.47 | 14.44 | 13.20 | 14.39 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 82.83 | 72.35 | 62.32 | 54.11 | 47.24 |
| Tax Rate(%) | 25.83 | 26.38 | 20.12 | 29.70 | 32.66 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.96 | 14.26 | 12.48 | 13.72 | 14.13 |
| EBIT Margin(%) | 8.70 | 11.22 | 9.22 | 10.28 | 10.73 |
| Pre Tax Margin(%) | 6.40 | 8.35 | 6.39 | 7.33 | 7.52 |
| PAT Margin (%) | 4.75 | 6.15 | 5.10 | 5.15 | 5.07 |
| Cash Profit Margin (%) | 7.98 | 10.08 | 8.79 | 9.05 | 8.66 |
| Performance Ratios | |||||
| ROA(%) | 5.65 | 6.07 | 5.74 | 5.78 | 6.36 |
| ROE(%) | 13.24 | 14.92 | 14.39 | 15.91 | 20.93 |
| ROCE(%) | 13.79 | 14.71 | 13.61 | 15.20 | 17.34 |
| Asset Turnover(x) | 1.19 | 0.99 | 1.13 | 1.12 | 1.26 |
| Sales/Fixed Asset(x) | 1.71 | 1.47 | 1.61 | 1.63 | 1.85 |
| Working Capital/Sales(x) | -48.16 | -19.65 | -18.83 | -29.31 | -16.38 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.58 | 0.68 | 0.62 | 0.61 | 0.54 |
| Receivable days | 50.35 | 61.56 | 58.46 | 71.83 | 61.33 |
| Inventory Days | 45.52 | 54.14 | 49.92 | 45.31 | 34.39 |
| Payable days | 66.51 | 85.60 | 68.24 | 75.70 | 57.63 |
| Valuation Parameters | |||||
| PER(x) | 12.54 | 10.67 | 15.48 | 6.94 | 15.68 |
| PCE(x) | 7.44 | 6.50 | 8.97 | 3.94 | 9.15 |
| Price/Book(x) | 1.55 | 1.48 | 2.08 | 0.96 | 2.79 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.88 | 0.96 | 1.15 | 0.64 | 1.16 |
| EV/Core EBITDA(x) | 7.09 | 6.36 | 8.95 | 4.54 | 8.09 |
| EV/EBIT(x) | 10.17 | 8.59 | 12.53 | 6.26 | 10.80 |
| EV/CE(x) | 1.30 | 1.26 | 1.53 | 0.95 | 1.23 |
| M Cap / Sales | 0.59 | 0.65 | 0.79 | 0.36 | 0.79 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 32.39 | -0.52 | 12.59 | 2.81 | 81.03 |
| Core EBITDA Growth(%) | 9.10 | 16.76 | 2.53 | 1.71 | 129.99 |
| EBIT Growth(%) | 2.62 | 21.09 | 0.96 | -1.51 | 250.08 |
| PAT Growth(%) | 2.25 | 19.89 | 11.49 | 4.54 | 2,378.51 |
| EPS Growth(%) | 2.24 | 19.87 | 11.50 | -10.66 | 2,062.37 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.78 | 0.73 | 0.99 | 0.82 | 1.41 |
| Current Ratio(x) | 0.95 | 0.87 | 0.88 | 0.91 | 0.88 |
| Quick Ratio(x) | 0.57 | 0.52 | 0.52 | 0.57 | 0.63 |
| Interest Cover(x) | 3.79 | 3.91 | 3.25 | 3.48 | 3.34 |
| Total Debt/Mcap(x) | 0.50 | 0.49 | 0.48 | 0.85 | 0.51 |
Compare Financial Ratios of peers of PARNAX LAB
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| PARNAX LAB | ₹122.0 Cr | -2.3% | -7% | -18.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹424,202.0 Cr | 0.5% | -2.9% | 5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹264,141.0 Cr | 5% | 7.2% | 49.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹174,402.0 Cr | -0.5% | -4.5% | 28.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,868.0 Cr | 2.7% | 8.4% | 5.1% | Stock Analytics | |
| CIPLA | ₹111,650.0 Cr | 2.4% | 2.4% | -12.9% | Stock Analytics | |
PARNAX LAB Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PARNAX LAB | -2.3% |
-7% |
-18.2% |
| SENSEX | 2.8% |
4.4% |
-10.1% |
You may also like the below Video Courses
